ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type.
AIDS Vaccines
/ chemistry
Adjuvants, Immunologic
/ pharmacology
Alum Compounds
/ pharmacology
Animals
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ immunology
Female
HIV Infections
Macaca mulatta
SAIDS Vaccines
/ chemistry
Simian Acquired Immunodeficiency Syndrome
Simian Immunodeficiency Virus
Viral Vaccines
/ chemistry
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
19
06
2019
accepted:
03
10
2019
entrez:
4
12
2019
pubmed:
4
12
2019
medline:
29
2
2020
Statut:
epublish
Résumé
The ALVAC-HIV clade B/AE and equivalent SIV-based/gp120 + Alum vaccines successfully decreased the risk of virus acquisition in humans and macaques. Here, we tested the efficacy of HIV clade B/C ALVAC/gp120 vaccine candidates + MF59 or different doses of Aluminum hydroxide (Alum) against SHIV-Cs of varying neutralization sensitivity in macaques. Low doses of Alum induced higher mucosal V2-specific IgA that increased the risk of Tier 2 SHIV-C acquisition. High Alum dosage, in contrast, elicited serum IgG to V2 that correlated with a decreased risk of Tier 1 SHIV-C acquisition. MF59 induced negligible mucosal antibodies to V2 and an inflammatory profile with blood C-reactive Protein (CRP) levels correlating with neutralizing antibody titers. MF59 decreased the risk of Tier 1 SHIV-C acquisition. The relationship between vaccine efficacy and the neutralization profile of the challenge virus appear to be linked to the different immunological spaces created by MF59 and Alum via CXCL10 and IL-1β, respectively.
Identifiants
pubmed: 31794588
doi: 10.1371/journal.ppat.1008121
pii: PPATHOGENS-D-19-01069
pmc: PMC6890176
doi:
Substances chimiques
AIDS Vaccines
0
ALVAC vaccine
0
Adjuvants, Immunologic
0
Alum Compounds
0
Antibodies, Neutralizing
0
Antibodies, Viral
0
SAIDS Vaccines
0
Viral Vaccines
0
aluminum sulfate
34S289N54E
Banques de données
figshare
['10.6084/m9.figshare.8298332']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1008121Subventions
Organisme : NIAID NIH HHS
ID : HHSN272201300033C
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201600012C
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201100022C
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI048240
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201100022I
Pays : United States
Commentaires et corrections
Type : ErratumIn
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Immunol Invest. 1997 Jan-Feb;26(1-2):15-28
pubmed: 9037609
Science. 2016 Apr 22;352(6284):aaf1098
pubmed: 27102489
J Immunol. 2005 Sep 15;175(6):3502-7
pubmed: 16148092
Nature. 1985 Jun 20-26;315(6021):672-6
pubmed: 3925348
PLoS One. 2018 Apr 26;13(4):e0194266
pubmed: 29698406
Infect Immun. 2001 Feb;69(2):1151-9
pubmed: 11160013
Nat Med. 2018 Oct;24(10):1590-1598
pubmed: 30177821
J Virol. 2015 Aug;89(16):8643-50
pubmed: 26018159
PLoS One. 2010 Jul 21;5(7):e11689
pubmed: 20657739
Proc Natl Acad Sci U S A. 2013 May 28;110(22):9019-24
pubmed: 23661056
J Virol. 2002 Jan;76(1):292-302
pubmed: 11739694
Curr Opin Infect Dis. 2006 Feb;19(1):1-7
pubmed: 16374210
J Immunol. 2016 Oct 1;197(7):2726-37
pubmed: 27591322
Nat Med. 2016 Jul;22(7):762-70
pubmed: 27239761
N Engl J Med. 2012 Apr 5;366(14):1275-86
pubmed: 22475592
N Engl J Med. 2013 Nov 28;369(22):2083-92
pubmed: 24099601
PLoS One. 2013 Sep 26;8(9):e75665
pubmed: 24086607
J Virol. 2013 Sep;87(18):10163-72
pubmed: 23843636
Nature. 2008 Jun 19;453(7198):1122-6
pubmed: 18496530
J Basic Clin Pharm. 2016 Mar;7(2):27-31
pubmed: 27057123
J Virol. 1998 Feb;72(2):1052-9
pubmed: 9444999
AIDS. 2011 Mar 13;25(5):679-89
pubmed: 21297424
Nat Med. 2018 Jun;24(6):847-856
pubmed: 29785023
N Engl J Med. 2009 Dec 3;361(23):2209-20
pubmed: 19843557
J Virol. 2013 Feb;87(3):1708-19
pubmed: 23175374
Vaccine. 2011 Nov 28;29(51):9538-43
pubmed: 22001122
PLoS Pathog. 2018 Feb 23;14(2):e1006888
pubmed: 29474461
Lancet. 2008 Nov 29;372(9653):1881-1893
pubmed: 19012954
Nature. 2012 Oct 18;490(7420):417-20
pubmed: 22960785
J Infect Dis. 2006 Dec 15;194(12):1661-71
pubmed: 17109337
Lancet Infect Dis. 2011 Jul;11(7):507-15
pubmed: 21570355
J Virol. 2014 Feb;88(3):1809-14
pubmed: 24257612
J Immunol. 2017 Nov 1;199(9):3293-3305
pubmed: 28947539
J Virol. 2018 Jul 17;92(15):
pubmed: 29793957
Lancet Infect Dis. 2012 Jul;12(7):531-7
pubmed: 22652344
J Virol. 2006 Apr;80(8):3732-42
pubmed: 16571790
PLoS Pathog. 2015 Aug 12;11(8):e1005101
pubmed: 26267144
Science. 2016 Oct 14;354(6309):197-202
pubmed: 27738167
Clin Infect Dis. 2017 Apr 15;64(8):1098-1104
pubmed: 28158448
Vaccine. 2006 Sep 29;24(40-41):6376-91
pubmed: 16859816
J Virol. 2006 Sep;80(17):8729-38
pubmed: 16912320
J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):270-7
pubmed: 16940858
Lancet HIV. 2018 Jul;5(7):e366-e378
pubmed: 29898870
Curr Protoc Immunol. 2005 Jan;Chapter 12:Unit 12.11
pubmed: 18432938